Telo Genomics (TDSGF) Stock News

Telo Genomics (OTCQB: TDSGF) presented a groundbreaking poster abstract on minimal residual disease (MRD) at the 22nd International Myeloma Society Annual Meeting in Toronto. The presentation introduced a novel workflow combining Multiple Myeloma (MM) Circulating Tumor Cells (CTCs) enumeration with TeloView® 3D telomere profiling platform.

The innovative methodology offers a less invasive biomarker for Multiple Myeloma by analyzing peripheral blood instead of bone marrow. This approach provides functional and biologically actionable data beyond traditional enumeration methods, helping assess disease progression risk. The abstract will be published in the Clinical Lymphoma, Myeloma, & Leukemia Journal.

Telo Genomics (OTCQB: TDSGF) has engaged Hayden IR, LLC as its investor relations consulting firm to enhance investor awareness and communication strategy. The 12-month agreement, effective August 20, 2025, includes a monthly fee of US$7,500.

For the first four months, US$3,500 of the monthly fee (totaling US$14,000) will be accrued and payable upon either Telo's next financing closing or January 31, 2026. The agreement includes a 30-day termination notice option for both parties.

Telo Genomics (OTCQB: TDSGF) announced its participation in the upcoming OTCQB Venture Virtual Investor Conference on August 7th, 2025. Guido Baechler, Executive Chairman of the Board, will present the company's strategy for accelerating development and commercialization of multiple myeloma MRD and smoldering myeloma assay applications.

The live, interactive presentation is scheduled for 1:00 PM - 1:30 PM ET, allowing investors to engage directly with the company through a Q&A session. An archived webcast will be available for those unable to attend the live event.

Telo Genomics (OTCQB: TDSGF) announced the acceptance of its abstract on minimal residual disease (MRD) for presentation at the 22nd International Myeloma Society Annual Meeting in Toronto, from September 17-20, 2025. The abstract, titled "3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression," will be presented by Dr. Yulia Shifrin and published in Clinical Lymphoma, Myeloma & Leukemia.

The presentation will showcase TeloView MM-MRD's proprietary approach to counting and profiling individual MRD cells, which could help clinicians assess relapse risk. Additionally, the company issued 411,539 common shares to Trusted Health Advisors LLC for services related to partnering and commercialization, valued at approximately $50,369.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced it has received a Statement of Claim from its former President, Sherif Louis, who is seeking approximately $530,000 in alleged unpaid notice and bonuses. The Company stated it intends to vigorously defend against the claim and will file a statement of defence and counterclaim in response.

The announcement represents a legal dispute between the Company and its former executive, with potential financial implications depending on the outcome of the legal proceedings.

Telo Genomics (TDSGF) has initiated a clinical trial for its TeloView MM-MRD assay at Cleveland Clinic Cancer Institute to assess minimal residual disease in multiple myeloma patients. This follows their initial MRD trial announced in February 2024 at McGill University. The TeloView MM-MRD test offers superior sensitivity in counting MRD cells and can profile individual cancer cell malignancy to help guide treatment decisions. The Cleveland Clinic collaboration expands patient recruitment, particularly for those receiving CAR-T therapies. With approximately 180,000 MM patients in North America requiring regular monitoring, the potential market reaches 800,000 tests annually. The collaboration may also validate other assays like TeloView SMM for smoldering MM patients.

Telo Genomics (TSXV: TELO) (OTCQB: TDSGF) has secured an enhanced client agreement with Intellectual Property Ontario (IPON). The company has qualified for a 2nd Tier client designation, increasing its IP funding access to $100,000 per fiscal year with a $300,000 lifetime cap, up from the previous $80,000 limit. Telo currently maintains a portfolio of 23 patents and pending applications across Canada, US, and Europe, with 20 fully granted. These patents cover their core 3D telomere technology TeloView and specific applications in hematological disorders, Alzheimer's disease, and liquid biopsy technology. The company is developing diagnostic and prognostic tests for Multiple Myeloma, Minimal Residual Disease, early-stage Alzheimer's disease, and prostate cancer. Their flagship TeloViewSMM test for smoldering myeloma is expected to have patent protection until 2043.

Telo Genomics Corp (TDSGF) announced that the European Hematology Association (EHA) has accepted their abstract for presentation at the EHA 2025 Congress. The abstract titled "Advanced Risk Prediction for Smoldering Multiple Myeloma (SMM) Patients" demonstrates improved risk assessment through combining Mayo Clinic's 2/20/20 model with TeloViewSMM. The study of 88 patients showed predictive accuracies of 0.64 for 2/20/20, 0.77 for TeloViewSMM, and 0.80 when used together. Dr. Shaji Kumar from Mayo Clinic will present the findings on June 14th. The research suggests TeloViewSMM could be integrated into existing FISH laboratory workflows, making the combined assessment approach both scalable and beneficial for clinical applications.

Telo Genomics (TSXV: TELO, OTCQB: TDSGF) announced the acceptance of its abstract submission by the American Society of Clinical Oncology (ASCO) for its 2025 Annual Meeting. The abstract focuses on concordance analysis between blood and marrow samples using the TeloView® Minimal Residual Disease (MRD) methodology.

The company's ongoing MRD clinical trials with McGill University/Jewish General Hospital aim to develop two prognostic tests: 1) identifying and quantifying MRD cells in patient's blood post marrow transplantation, and 2) profiling isolated circulating MRD cells using TeloView® technology to assess disease aggressiveness. Both tests are designed as liquid biopsy-based solutions.

This development follows the FDA's Oncologic Drugs Advisory Committee's unanimous vote in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies.